Elite Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Elite Pharmaceuticals generated cash of -$3,281,558, which is less than the previous year. Cash used in financing activities reached the amount of $3,385,624 last year. Net change in cash is therefore -$705,587.
Cash Flow
| 2015 | -15.10M | 2.87M | 12.74M |
|---|---|---|---|
| 2016 | -2.76M | -1.94M | 8.76M |
| 2017 | -7.88M | -1.10M | 8.07M |
| 2018 | -4.80M | -277.33K | 1.67M |
| 2019 | -6.79M | 330.87K | 1.56M |
| 2020 | -1.79M | -34.95K | 689.53K |
| 2021 | 3.19M | -262.78K | -869.82K |
| 2022 | 6.50M | -498.56K | -667.13K |
| 2023 | 3.33M | -5.73M | 1.70M |
| 2024 | -3.28M | -809.65K | 3.38M |
ELTP Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.24M | 8.94M | 3.59M | 1.53M | 2.67M | 7.57M | 10.59M | 11.51M | 7.46M | 6.94M |
Operating activities | ||||||||||
Net income | 20.10M | 3.56M | 8.89M | 5.08M | -2.24M | -9.27M | -3.67M | 3.81M | -683.01K | 28.92M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.47M | 1.34M | 1.43M | 1.52M | 1.51M | 1.25M | 996.40K | 714.53K | 666.46K | 581.85K |
Stock-based compensation expense | 8.51M | 579.32K | 781.47K | 935.62K | 1.02M | 1.71M | 1.16M | 767.70K | 907.03K | 260.04K |
| Deferred income tax benefit | 8.51M | 579.32K | 781.47K | 935.62K | 1.02M | 1.71M | 1.16M | 767.70K | 907.03K | 260.04K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -16.59M | -36.63K | 438.46K | 610.47K | -2.78M | -545.92K | 258.18K | 596.23K | 33.24K | -714.36K |
Inventories | -3.37M | -2.80M | -1.72M | -870.43K | 373.25K | 382.27K | 1.51M | -3.12M | -261.72K | -1.09M |
Accounts payable | 7.78M | 1.33M | 314.21K | -1.76M | 344.39K | 61.00K | 677.26K | -925.08K | -2.21M | 1.81M |
Cash generated by operating activities | -3.28M | 3.33M | 6.50M | 3.19M | -1.79M | -6.79M | -4.80M | -7.88M | -2.76M | -15.10M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -2.48K | -122 | 0 | 0 |
Investments In Property Plant And Equipment | -809.65K | -5.73M | -498.56K | -329.98K | -34.95K | -19.13K | -274.84K | -1.10M | -1.94M | -1.99M |
Acquisitions Net | 0 | 0 | 0 | 67.2K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -809.65K | -5.73M | -498.56K | -262.78K | -34.95K | 330.87K | -277.33K | -1.10M | -1.94M | 2.87M |
Financing activities | ||||||||||
Common Stock Issued | 159.92M | 39.32M | 14.35M | 42.22K | 1.43M | 2.06M | 1.99M | 7.59M | 6.19M | 13.23M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 3.33M | 1.70M | -667.13K | -1.92M | -748.44K | -496.68K | -632.49K | -1.33M | -614.13K | -1.27M |
Cash used in financing activities | 3.38M | 1.70M | -667.13K | -869.82K | 689.53K | 1.56M | 1.67M | 8.07M | 8.76M | 12.74M |
Net Change In Cash | -705.58K | -695.71K | 5.34M | 2.06M | -1.13M | -4.89M | -3.41M | -917.48K | 4.04M | 522.40K |
Cash at end of period | 7.53M | 8.24M | 8.94M | 3.59M | 1.53M | 2.67M | 7.17M | 10.59M | 11.51M | 7.46M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |